Clinical Trial: Mirdametinib in Histiocytic Disorders
Study Status: Completed
Recruit Status: RECRUITING
Condition: Langerhans Cell Histiocytosis (LCH)
Study Type: INTERVENTIONAL
Official Title: A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders
Brief Summary:
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
Read more